Vaxcyte (PCVX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.26 (+0.28%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Vaxcyte (PCVX)
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.

Key Insights

Critical company metrics and information
  • Share Price

    $92.32
  • Market Cap

    $11.51 Billion
  • Total Outstanding Shares

    124.64 Million Shares
  • Total Employees

    254
  • Dividend

    No dividend
  • IPO Date

    June 12, 2020
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.vaxcyte.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-470.04 Million
Net Cash Flow, Continuing$513.88 Million
Net Cash Flow From Financing Activities$2.45 Billion
Net Cash Flow From Operating Activities, Continuing$-470.04 Million
Exchange Gains/Losses$-8.61 Million
Net Cash Flow$505.27 Million
Net Cash Flow From Investing Activities$-1.46 Billion
Net Cash Flow From Financing Activities, Continuing$2.45 Billion
Net Cash Flow From Investing Activities, Continuing$-1.46 Billion

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Depreciation and Amortization$5.00 Million
Diluted Earnings Per Share$-4.60
Other Operating Expenses$151.77 Million
Diluted Average Shares$119.39 Million
Net Income/Loss Attributable To Parent$-507.65 Million
Basic Average Shares$119.39 Million
Income/Loss From Continuing Operations Before Tax$-507.65 Million
Basic Earnings Per Share$-4.60
Research and Development$447.18 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Revenues$0.00
Income/Loss From Continuing Operations After Tax$-507.65 Million
Operating Income/Loss$-604.05 Million
Net Income/Loss$-507.65 Million
Operating Expenses$604.05 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss Available To Common Stockholders, Basic$-507.65 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Assets$1.35 Billion
Noncurrent Liabilities$18.32 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Liabilities$93.33 Million
Equity Attributable To Parent$3.42 Billion
Other Non-current Assets$1.18 Billion
Non-current Prepaid Expenses$284,000.00
Prepaid Expenses$10.59 Million
Fixed Assets$163.24 Million
Equity$3.42 Billion
Other Current Assets$2.20 Billion
Liabilities And Equity$3.56 Billion
Liabilities$142.11 Million
Current Assets$2.21 Billion
Accounts Payable$18.22 Million
Assets$3.56 Billion
Current Liabilities$123.79 Million
Wages$12.24 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.